Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Mai 2018 06:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports First Quarter 2018 Results and Highlights

NDA submission for Gimoti™ on track for second quarter of 2018Announced discovery of sex-based pharmacokinetic differences for GimotiWaiver of the PDUFA fee for Gimoti NDA granted by FDACash runway...
10. Mai 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

SOLANA BEACH, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...
30. April 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Granted First Gender Specific Patent for Gimoti™

SOLANA BEACH, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
26. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

SOLANA BEACH, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
07. März 2018 16:05 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights

Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ doseAnnounced discovery of sex-based pharmacokinetic differences for Gimoti™Met with FDA...
06. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma to Present at the Upcoming Roth and Oppenheimer Investor Conferences

SOLANA BEACH, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
05. März 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application

SOLANA BEACH, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
21. Februar 2018 08:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2017 Financial Results

SOLANA BEACH, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, announced today that...
15. Februar 2018 07:30 ET | Quelle: Evoke Pharma, Inc.

Evoke Announces Discovery of Sex-Based Pharmacokinetic Differences for Gimoti™

SOLANA BEACH, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
14. November 2017 16:05 ET | Quelle: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2017 Results and Highlights

Announced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti™505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filingPartnered with the Patheon...

Vorherige Seite